Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Saracatinib

Alternative Names: saracatinib, azd0530, saracatinab
Clinical Status: Active
Latest Update: 2025-04-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: SRC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Saracatinib

Countries in Clinic: Germany, Netherlands, United Kingdom, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Fibrodysplasia Ossificans Progressiva|Idiopathic Pulmonary Fibrosis|Myositis Ossificans

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
STOPFOP

P2

Recruiting

Myositis Ossificans|Fibrodysplasia Ossificans Progressiva

2025-05-06

12%

2024-05-04

STOP-IPF

P2

Active, not recruiting

Idiopathic Pulmonary Fibrosis

2024-09-15

24%

2024-04-27

Primary Endpoints

Recent News Events

Date

Type

Title

07/30/2024

News Article

 New Study Describes a Functional, Aged, Human Cell-Based Platform That Examines the Contribution of Senescence in Alzheimer's Disease Progression, and Response to Therapeutics

05/02/2024

PubMed

 Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations.

04/22/2024

PubMed

 Dual Drug Repurposing: The Example of Saracatinib.

03/14/2024

PubMed

 Deficiency of Nuclear Receptor Coactivator 3 Aggravates Diabetic Kidney Disease by Impairing Podocyte Autophagy.

06/08/2023

News Article

 Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

05/02/2023

News Article

 Orphan drugs market to grow by USD 170.8 billion between 2022 and 2027; Growth driven by rising incidence of rare diseases - Technavio

01/17/2022

News Article

 Global Idiopathic Pulmonary Fibrosis (IPF) Market Pipeline Report 2021 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions